Year |
Citation |
Score |
2012 |
James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, ... ... Williams M, et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Molecular Cancer Therapeutics. 11: 930-41. PMID 22319199 DOI: 10.1158/1535-7163.MCT-11-0645 |
0.434 |
|
2012 |
Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC, Gunawardane RN, Nepomuceno RR, ... ... Williams M, et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. Journal of Medicinal Chemistry. 55: 1082-105. PMID 22168626 DOI: 10.1021/jm2009925 |
0.449 |
|
2011 |
Holladay MW, Campbell BT, Rowbottom MW, Chao Q, Sprankle KG, Lai AG, Abraham S, Setti E, Faraoni R, Tran L, Armstrong RC, Gunawardane RN, Gardner MF, Cramer MD, Gitnick D, ... ... Williams M, et al. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 5342-6. PMID 21807507 DOI: 10.1016/j.bmcl.2011.07.019 |
0.432 |
|
Show low-probability matches. |